Efficacy and Safety of Left Atrial Appendage Occlusion in Mild Mitral Stenosis Patients with High Bleeding Risk
-
- Lan Beidi
- Department of Structural Heart Disease, The First Affiliated Hospital of Xi'an Jiaotong University
-
- Cheng Gesheng
- Department of Structural Heart Disease, The First Affiliated Hospital of Xi'an Jiaotong University
-
- Bai Yuan
- Department of Cardiology, Changhai Hospital of the Navy Military Medical University
-
- Du Yajuan
- Department of Structural Heart Disease, The First Affiliated Hospital of Xi'an Jiaotong University
-
- Xie Xuegang
- Department of Structural Heart Disease, The First Affiliated Hospital of Xi'an Jiaotong University
-
- Ma Yuying
- Department of Structural Heart Disease, The First Affiliated Hospital of Xi'an Jiaotong University
-
- Zeng Haowei
- Department of Structural Heart Disease, The First Affiliated Hospital of Xi'an Jiaotong University
-
- He Lu
- Department of Structural Heart Disease, The First Affiliated Hospital of Xi'an Jiaotong University
-
- Xie Hang
- Department of Structural Heart Disease, The First Affiliated Hospital of Xi'an Jiaotong University
-
- He Xumei
- Department of Structural Heart Disease, The First Affiliated Hospital of Xi'an Jiaotong University
-
- Song Qiang
- Department of Structural Heart Disease, The First Affiliated Hospital of Xi'an Jiaotong University
-
- Zhang Yushun
- Department of Structural Heart Disease, The First Affiliated Hospital of Xi'an Jiaotong University
書誌事項
- タイトル別名
-
- Three-Year Outcome
説明
<p>Atrial fibrillation (AF) is highly prevalent in patients with mitral stenosis (MS), but the efficacy of left atrial appendage occlusion (LAAO) in these patients remains unclear.</p><p>The aim of this study was to evaluate the efficacy and safety of LAAO in patients with MS complicated by AF at high risk of bleeding.</p><p>We recruited patients from September 2015 to September 2018. We compared the 3-year outcomes of LAAO in 21 patients with AF complicated by MS and 42 sex- and age-matched patients with AF without MS.</p><p>The MS group had more cases of peripheral arterial embolism (28.6% versus 2.4%, P = 0.004), more spontaneous echo contrast (47.6% versus 9.5%, P = 0.001), a larger LAA orifice diameter (P < 0.01), and a slower LAA flow (P < 0.05) than the Non-MS group. The mean size of the selected occluder device was bigger for patients with MS than for patients with Non-MS (29.2 ± 3.7 versus 26.9 ± 3.1 mm, P = 0.014). In the first 45 follow-up days, 2 (9.5%) patients with MS had device-related thrombi (DRT); one of them had transient ischemic attack 24 hours postoperatively. From 45 days to 6 months, one patient in each group had DRT. After 6 months, two patients in the Non-MS group still had residual leaks; one of them had a stroke, with a small DRT. The proportion of dual antiplatelet therapy was higher in the Non-MS group than in the MS group (33.3% versus 4.8%, P = 0.012), but this population had an increased bleeding risk.</p><p>LAAO is relatively effective and safe for preventing embolic events in patients with MS complicated by AF, at high risk of bleeding.</p>
収録刊行物
-
- International Heart Journal
-
International Heart Journal 63 (3), 492-497, 2022-05-30
一般社団法人 インターナショナル・ハート・ジャーナル刊行会
